The STEP clinical trial program demonstrated that semaglutide consistently produced 10.9% to 14.9% weight loss across diverse patient populations, with 83.5% of participants achieving clinically meaningful weight loss of 5% or more
It also connects to 60 chronic health conditions, including Hashimotos and hypothyroidism, blood clots, infertility, cardiovascular disease, Alzheimers, depression, birth defects, and certain cancers
Like all medications, they carry potential side effects and should only be taken when prescribed appropriately
A doctor-formulated prebiotic and probiotic designed to support digestive comfort and overall well-being during your GLP-1 journey.*
Replication in a larger sample, especially for the nominal associations, would be worthwhile